natgillin/translations-raw huggingface dataset:
Linearity: Systemic exposure of rosuvastatin increases in proportion to dose. 
Linearnost: Sistemska izpostavljenost rosuvastatinu se zvečuje proporcionalno z njegovim odmerkom.
<[See Annex I- to be completed nationally]> 
<Glejte Dodatek I - Izpolni država članic]>
Before Treatment 
Pred zdravljenjem
The assessment of relevance of this incremental reduction is complex, and must take into account the body of evidence available from outcome trials for this class of agents. 
Vrednotenje pomena tega povečevanja učinka znižanja je zapleteno, upoštevati pa mora dokaze, ki so pridobljeni v preskušanjih izida za to skupino zdravil.
This small increase is not considered clinically significant. 
To zvečanje ni klinično pomembno.
However, based on its pharmacodynamic properties, Crestor is unlikely to affect this ability. 
Na podlagi njegovih farmakodinamičnih lastnosti pa je malo verjetno, da bi vplival na to sposobnost.
Round, yellow coloured, intagliated with 'ZD4522' and '5' on one side and plain on the reverse. 
Okrogla, rumena, z oznakama 'ZD4522' in '5' na eni strani, na drugi strani pa brez oznak.
When driving vehicles or operating machines, it should be taken into account that dizziness may occur during treatment. 
Med vožnjo motornih vozil ali delom s stroji se je treba zavedati, da se lahko med zdravljenjem pojavi vrtoglavica.
Skeletal Muscle Effects 
Vpliv na skeletno mišičje
Other medicinal products: Based on data from specific interaction studies no clinically relevant interaction with digoxin is expected. 
Druga zdravila: Na osnovi podatkov specifičnih študij medsebojnega delovanja ni pričakovati klinično pomembnih interakcij z digoksinom.
Concomitant administration did not affect plasma concentrations of cyclosporin. 
Sočasna uporaba ne vpliva na plazemske koncentracije ciklosporina.
Before treatment initiation the patient should be placed on a standard cholesterol-lowering diet that should continue during treatment. 
Pred začetkom zdravljenja je potrebno bolniku predpisati standardno dieto za zmanjševanje vrednosti holesterola, ki jo mora nadaljevati tudi med zdravljenjem.
The volume of distribution of rosuvastatin is approximately 134 L. Approximately 90% of rosuvastatin is bound to plasma proteins, mainly to albumin. 
Porazdelitveni volumen rosuvastatina je približno 134 l. Na plazemske beljakovine se ga veže približno 90 %, v glavnem na albumin.
Crestor 5 mg film-coated tablets. 
Crestor 5 mg, filmsko obložene tablete
If a patient becomes pregnant during use of this product, treatment should be discontinued immediately. 
Če bolnica med zdravljenjem s tem zdravilom zanosi, ga mora takoj prenehati uporabljati.
The maximum response is usually achieved by 4 weeks and is maintained after that. 
Učinek je običajno največji po štirih tednih zdravljenja, nato pa tak tudi ostane.
Uncommon (>1/1,000, <1/100); Rare (>1/10,000, <1/1000); 
< 1/100) in redke (> 1/10.000, < 1/1.000).
However, the combination has been extensively used in women in clinical trials and was well tolerated. 
Kljub temu pa je bila njuna kombinacija v kliničnih preskušanjih zelo pogosta, preiskovanke pa so jo dobro prenašale.
In patients with secondary hypercholesterolaemia caused by hypothyroidism or nephrotic syndrome, the underlying disease should be treated prior to initiating therapy with Crestor. 
Pri bolnikih s sekundarno hiperholesterolemijo, ki je posledica hipotiroidizma ali nefrotskega sindroma, je treba pred začetkom uporabe Crestorja najprej zdraviti osnovno bolezen.
A dose adjustment to the next dose level can be made after 4 weeks, if necessary (see Section 5.1 Pharmacodynamic properties). 
Odmerek se lahko po potrebi prilagodi na naslednjo stopnjo po štirih tednih zdravljenja (glejte poglavje 5.1 Farmakodinamične lastnosti).
A population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics between Caucasian and Black groups. 
V populacijski farmakokinetični analizi niso odkrili klinično pomembnih razlik pri farmakokinetičnih lastnostih belcev in črncev.
Rather, the choice of start dose should take into account potential safety concerns in the individual patient based e.g. on sensitivity to adverse reactions and pharmacokinetic considerations. 
Bolje je, da se pri izbiri začetnega odmerka upošteva potencialne zadržke glede varnosti pri posameznem bolniku na podlagi, npr. občutljivosti za neželene reakcije in farmakokinetične zadržke.
This interaction may be caused by the increase in gut motility caused by erythromycin. 
Interakcija je morda posledica zvečanja črevesne motilitete, ki jo povzroča eritromicin.
Immune system disorders Rare: hypersensitivity reactions including angioedema 
Bolezni imunskega sistema redki: preobčutljivostne reakcije, tudi angioedem
In most cases, proteinuria decreases or disappears spontaneously on continued therapy, and has not been shown to be predictive of acute or progressive renal disease. 
Pri večini primerov se zvečana vrednost beljakovin v seču med kontinuiranim zdravljenjem zmanjša ali normalizira spontano in ne napoveduje akutne ali napredujoče ledvične bolezni.
Crestor should be discontinued or the dose reduced if the level of serum transaminases is greater than 3 times the upper limit of normal. 
Zdravljenje s Crestorjem je treba ustaviti ali pa njegov odmerek zmanjšati, če serumske vrednosti transaminaz presegajo trikratno zgornjo mejo normalne vrednosti.
Antacid: The simultaneous dosing of Crestor with an antacid suspension containing aluminium and magnesium hydroxide resulted in a decrease in rosuvastatin plasma concentration of approximately 50%. 
Antacid: Med sočasno uporabo Crestorja in suspenzije antacida, ki vsebuje aluminijev in magnezijev hidroksid, se plazemska koncentracija rosuvastatina zmanjša za približno 50 %.
There are no data with respect to excretion in milk in humans. 
Podatkov o njegovem izločanju v mleko pri ženskah ni
(See sections 4.4 Special warnings and special precautions for use, 4.5 Interaction with other medicinal products and other forms of interaction and 5.2 Pharmacokinetic properties). 
(Glejte poglavja 4.4 Posebna opozorila in previdnostni ukrepi, 4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij in 5.2 Farmakokinetične lastnosti).
Since cholesterol and other products of cholesterol biosynthesis are essential for the development of the foetus, the potential risk from inhibition of HMG-CoA reductase outweighs the advantage of treatment during pregnancy. 
Ker so holesterol in drugi produkti, ki nastanejo pri njegovi biosintezi, nujno potrebni za plodov razvoj, morebitna nevarnost zaviranja reduktaze HMG-CoA pretehta prednosti zdravljenja med nosečnostjo.
The adverse events seen with Crestor are generally mild and transient. 
Neželeni učinki, ki se pojavijo med zdravljenjem s Crestorjem, so na splošno blagi in prehodni.
The recommended start dose is 5 mg for patients of Japanese and Chinese ancestry. 
Priporočen začetni odmerek za bolnike japonskega in kitajskega rodu je 5 mg.
These effects were observed at maternotoxic doses at systemic exposures several times above the therapeutic exposure level. 
Te učinke so opazili po uporabi toksičnih odmerkov za samico, po sistemski izpostavljenosti, ki je bila nekajkrat večja od terapevtske.
Animal studies provide limited evidence of reproductive toxicity (see Section 5.3 
raziskavah pri živalih so ugotovili, da so podatki o reproduktivni toksičnosti omejeni (glejte poglavje
- in patients with active liver disease including unexplained, persistent elevations of serum transaminases and any serum transaminase elevation exceeding 3 x the upper limit of normal 
- pri bolnikih z aktivno jetrno boleznijo, tudi nepojasnjenim persistentnim zvečanjem serumske vrednosti transaminaz in kakršnim koli zvečanjem serumske vrednosti transaminaz, ki presega trikratno zgornjo mejo normalne vrednosti (Upper limit of normal - ULN)
Therefore, Crestor is not recommended for paediatric use at this time. 
Zaradi tega uporaba Crestorja pri otrocih zaenkrat še ni priporočena.
Creatine Kinase Measurement 
Merjenje kreatin-kinaze
Women of child bearing potential should use appropriate contraceptive measures. 
Ženske v rodnem obdobju morajo uporabljati primerno kontracepcijsko zaščito.
These increased plasma levels should be considered when selecting oral contraceptive doses. 
Zvečanje teh plazemskih vrednosti je treba upoštevati pri določanju odmerkov peroralnih kontraceptivov.
The frequencies of adverse events are ranked according to the following: Common (>1/100, <1/10); 
Neželeni učinki so glede na pogostost razdeljeni na: pogoste (> 1/100, < 1/10), občasne (> 1/1.000,
Based on data from specific interaction studies no pharmacokinetic relevant interaction with fenofibrate is expected, however a pharmacodynamic interaction may occur. 
Na osnovi podatkov specifičnih študij medsebojnega delovanja ni pričakovati farmakokinetično pomembnih interakcij s fenofibratom, medtem ko se farmakodinamične interakcije lahko pojavijo.
The overall experience with rosuvastatin 5 mg is more limited than that with 10 mg but available clinical trials information and post-marketing data do not support relevant safety benefit at group level of the 5 mg dose, in comparison with the 10 mg dose. 
V celoti je izkušenj z odmerkom rosuvastatina 5 mg manj kot tistih za 10 mg, vendar dostopni podatki iz kliničnih preskušanj in postmarketinški podatki ne podpirajo ustrezne varnostne koristi odmerka 5 mg na ravni skupin v primerjavi z odmerkom 10 mg.
Studies to determine the effect of Crestor on the ability to drive and use machines have not been conducted . 
4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Študije o vplivu Crestorja na sposobnost vožnje in upravljanja s stroji niso bile izvedene.
No clinically relevant interactions have been observed between rosuvastatin and either fluconazole (an inhibitor of CYP2C9 and CYP3A4) or ketoconazole (an inhibitor of CYP2A6 and 
Ni klinično pomembnih interakcij med rosuvastatinom in flukonazolom (zaviralcem CYP2C9 in CYP3A4) ali ketokonazolom (zaviralcem CYP2A6 in CYP3A4).
Cyclosporin: During concomitant treatment with Crestor and cyclosporin, rosuvastatin AUC values were on average 7 times higher than those observed in healthy volunteers (see Section 4.3 Contraindications). 
Ciklosporin: Med sočasnim zdravljenjem s Crestorjem in ciklosporinom je vrednost AUC rosuvastatina povprečno sedemkrat večja kot pri zdravih prostovoljcih (glejte poglavje 4.3 Kontraindikacije).
Age and sex: There was no clinically relevant effect of age or sex on the pharmacokinetics of rosuvastatin. 
Starost in spol: Starost in spol nimata klinično pomembnega vpliva na farmakokinetiko rosuvastatina.
In addition, rosuvastatin is a poor substrate for these isoenzymes. 
Poleg tega je slab substrat za te izoencime.
The elimination half-life does not increase at higher doses. 
Razpolovna doba izločanja se z zvečanjem odmerka ne zveča.
The Ndesmethyl metabolite is approximately 50% less active than rosuvastatin whereas the lactone form is considered clinically inactive. 
N-demetilni presnovek je približno 50 % manj aktiven kot rosuvastatin, laktonski pa je klinično neaktiven.
The dose should be individualised according to the goal of therapy and patient response, using current consensus guidelines. 
Odmerjanje je individualno, v skladu s ciljem zdravljenja in bolnikovim odzivom nanj ter veljavnimi smernicami.
It is not considered necessary to request a generally higher ratio between start dose and maximum dose for rosuvastatin (20 mg in the general target population, 40 mg in selected patients) than has been requested for other statins assessed by CHMP (simvastatin, pravastatin). 
Velja mnenje, da ni potrebno zahtevati splošno večjega razmerja med začetnim odmerkom in največjim odmerkom rosuvastatina (20 mg v splošni ciljni populaciji, 40 mg pri posebnih bolnikih) od tistega, ki ga je Odbor za zdravila za uporabo v humani medicini zahteval za druge statine (simvastatin, pravastatin).
Use in the elderly 
Uporaba pri otrocih
Crestor is effective in adults with hypercholesterolaemia, with and without hypertriglyceridaemia, 
Crestor je učinkovit pri zdravljenju odraslih s hiperholesterolemijo s hipertrigliceridemijo ali brez nje,
Rosuvastatin has not been proven to prevent the associated complications of lipid abnormalities, such as coronary heart disease as mortality and morbidity studies with Crestor have not yet been completed. 
Dokazov o preventivnem delovanju rosuvastatina na zaplete zaradi nenormalnih vrednosti lipidov, npr. koronarno srčno bolezen, ni, kajti raziskave o umrljivosti in zbolevnosti še niso končane.
Crestor should not be used in any patient with an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (e.g. sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders; or uncontrolled seizures). 
Crestorja ne smejo jemati bolniki s hudo akutno boleznijo, ki bi utegnila biti miopatija ali bi lahko povzročila razvoj ledvične odpovedi zaradi rabdomiolize (npr. sepsa, hipotenzija, obsežen kirurški poseg, poškodba, hude presnovne, endokrine in elektrolitske motnje; nenadzorovani krči).
The 40 mg dose is contraindicated with concomitant use of a fibrate. 
Uporaba 40 mg odmerka je kontraindicirana pri sočasni uporabi s fibrati.
The geometric mean plasma clearance is approximately 50 litres/hour (coefficient of variation 21.7%). 
50 litrov/uro (koeficient variacije: 21,7 %).
Therefore, drug interactions resulting from cytochrome P450-mediated metabolism are not expected. 
Interakcij, ki so posledica presnove s pomočjo citokroma P450, zato ni pričakovati.
In light of the increased reporting rate of adverse reactions with the 40 mg dose compared to lower doses (see Section 4.8 Undesirable effects), a final titration to the maximum dose of 40 mg should only be considered in patients with severe hypercholesterolaemia at high cardiovascular risk (in particular those with familial hypercholesterolaemia), who do not achieve their treatment goal on 20 mg, and in whom routine follow up will be performed (see Section 4.4 Special warnings and precautions). 
Glede na povečano število poročil o neželenih učinkih pri uporabi 40 mg odmerkov v primerjavi z nižjimi odmerki (glejte poglavje 4.8 Neželeni učinki) je končna titracija na največji odmerek 40 mg potrebna le pri bolnikih s hudo hiperholesterolemijo in velikim kardiovaskularnim tveganjem (še posebej pri tistih z družinsko hiperholesterolemijo), pri katerih z uporabo 20-miligramskega odmerka cilj zdravljenja ni bil dosežen; te bolnike je treba rutinsko spremljati (glejte poglavje 4.4 Posebna opozorila in previdnostni ukrepi).
Therapy should be discontinued if CK levels are markedly elevated (>5xULN) or if muscular symptoms are severe and cause daily discomfort (even if CK levels are ≤ 5x ULN). 
če je njena vrednost bistveno zvečana (> 5x ULN) ali če so mišični simptomi hudi in motijo dnevne dejavnosti (četudi je vrednost CK ≤ 5x ULN).
For excipients see 6.1. 
Za pomožne snovi glejte poglavje 6.1.
The plasma elimination half-life is approximately 19 
Plazemska razpolovna doba izločanja traja približno 19 ur.
As with other HMG-CoA reductase inhibitors, Crestor should be used with caution in patients who consume excessive quantities of alcohol and/or have a history of liver disease. 
Tako kot druge zaviralce reduktaze HMG-CoA je treba tudi Crestor uporabljati zelo previdno pri bolnikih, ki popijejo veliko alkoholnih pijač in/ali imajo jetrno bolezen v anamnezi.
There are no pharmacokinetic data available in subjects taking concomitant Crestor and HRT and therefore a similar effect cannot be excluded. 
Farmakokinetičnih podatkov o ženskah, ki sočasno uporabljajo Crestor in imajo NHZ ni, zato možnosti podobnega učinka ni možno izključiti.
Following titration to a daily dose of 40 mg (12 weeks of treatment), LDL-C 
Po titriranju dnevnega odmerka na 40 mg (12 tednov zdravljenja) se je vrednost holesterola LDL zmanjšala za 53 %.
Whilst on Treatment 
Med zdravljenjem
33% of patients reached EAS guidelines for LDL-C levels (<3 mmol/l). 
33 % bolnikov je doseglo ciljno vrednost holesterola LDL (< 3 mmol/l), kakor jo določajo smernice EAS.
Paediatric experience is limited to a small number of children (aged 8 years or above) with homozygous familial hypercholesterolaemia. 
Zdravilo je jemalo le majhno število otrok (starih najmanj osem let) s homozigotno družinsko hiperholesterolemijo.
In the overall population, the mean LDL-C reduction was 22%. 
Srednja vrednost holesterola LDL se je v celotni populaciji zmanjšala za 22 %.
The choice of start dose should take into account the individual patient's cholesterol level and future cardiovascular risk as well as the potential risk for adverse reactions (see below). 
Pri odločitvi o začetnem odmerku je potrebno upoštevati vrednosti holesterola posameznega bolnika in njegovo bodoče kardiovaskularno tveganje kot tudi možno tveganje zaradi neželenih učinkov
- in patients with hypersensitivity to rosuvastatin or to any of the excipients. 
- pri bolnikih, ki so preobčutljivi za rosuvastatin ali katero koli pomožno snov zdravila
Erythromycin: Concomitant use of Crestor and erythromycin resulted in a 20% decrease in AUC (0-t) and a 30% decrease in Cmax of rosuvastatin. 
Eritromicin: Zaradi sočasne uporabe Crestorja in eritromicina se AUC rosuvastatina (0-t) zmanjša za 20 %, Cmax pa za 30 %.
Contraindications and Section 5.2 Pharmacokinetic properties). 
4.3 Kontraindikacije in poglavje 5.2 Farmakokinetične lastnosti).
In a large study, 435 patients with heterozygous familial hypercholesterolaemia were given Crestor from 20 mg to 80 mg in a force-titration design. 
V veliki raziskavi je 435 bolnikov s heterozigotno družinsko hiperholesterolemijo na podlagi načrta o forsiranem titriranju odmerka prejemalo 20 do 80 mg Crestorja.
In a force-titration, open label trial, 42 patients with homozygous familial hypercholesterolaemia were evaluated for their response to Crestor 20 - 40 mg. 
V odprti raziskavi z določanjem odmerka na podlagi forsiranega titriranja so pri 42 bolnikih s homozigotno družinsko hiperholesterolemijo ocenjevali njihov odziv na zdravljenje z 20- do 40miligramskimi odmerki Crestorja.
Creatine Kinase (CK) should not be measured following strenuous exercise or in the presence of a plausible alternative cause of CK increase which may confound interpretation of the result. 
Kreatin-kinaze (CK) se ne sme meriti po napornem razgibavanju ali če obstaja drug možen vzrok zvečanja vrednosti CK, ki lahko vpliva na izvid.
Rosuvastatin increases the number of hepatic LDL receptors on the cell-surface, enhancing uptake and catabolism of LDL and it inhibits the hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles. 
Rosuvastatin zvečuje število jetrnih receptorjev za LDL na površini celice in zveča prevzem in katabolizem LDL ter zavira nastajanje VLDL v jetrih in tako zmanjša skupno število delcev VLDL in
6.6 Instructions for use and handling < and disposal> No special requirements. 
6.6 Navodila za pripravo in ravnanje z zdravilom <in odlaganje>
It also lowers ApoB, nonHDL-C, VLDL-C, VLDL-TG and increases ApoA-I (see Table 1). 
Znižuje tudi raven ApoB, neHDL holesterola, holesterola VLDL, VLDL-TG in zvišuje raven ApoA-I (glejte preglednico 1).
The 40 mg dose is contraindicated in patients with pre-disposing factors for myopathy/rhabdomyolysis. 
Uporaba 40 mg odmerkov je kontraindicirana pri bolnikih, pri katerih je prisoten kateri od predispozicijskih dejavnikov za miopatijo/rabdomiolizo.
Proteinuria, detected by dipstick testing and mostly tubular in origin, has been observed in patients treated with higher doses of Crestor, in particular 40 mg, where it was transient or intermittent in most cases. 
Proteinurija, ki so jo odkrili s testiranjem s testnimi lističi in je bila v glavnem tubulna, se je pojavila pri bolnikih, ki so dobivali velike odmerke Crestorja, zlasti 40-miligramske; pri večini bolnikov je bila prehodna ali intermitentna.
In conclusion, the benefit/risk ratio is favourable for Crestor 5 or Crestor 10 mg as alternative start doses. 
Zaključimo lahko, da je razmerje med koristmi in tveganji za zdravili Crestor 5 ali Crestor 10 mg kot alternativnima začetnima odmerkoma ugodno.
Oral contraceptive/hormone replacement therapy (HRT): Concomitant use of Crestor and an oral contraceptive resulted in an increase in ethinyl oestradiol and norgestrel AUC of 26% and 34%, respectively. 
Peroralni kontraceptivi/nadomestno hormonsko zdravljenje (NHZ): Med hkratno uporabo Crestorja in peroralnih kontraceptivov se AUC etinilestradiola zveča za 26 %, norgestrela pa za 34 %.
This transporter is important in the hepatic elimination of rosuvastatin. 
Ta prenosnik je pomemben pri izločanju rosuvastatina prek jeter.
Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor for cholesterol. 
Rosuvastatin je selektiven in kompetitiven zaviralec reduktaze HMG-CoA, encima, ki določa hitrost pretvorbe 3-hidroksi-3-metilglutaril koencima A v mevalonat, ki je prekurzor holesterola.
However, two subjects with Child-Pugh scores of 8 and 9 showed an increase in systemic exposure of at least 2-fold compared to subjects with lower Child-Pugh scores. 
Pri dveh preiskovancih, ocenjenih z 8 in 9 točkami po Child-Pughovi lestvici, je bila sistemska izpostavljenost najmanj dvakrat večja kot pri tistih z nižjo oceno po tej lestvici.
Crestor reduces elevated LDL-cholesterol, total cholesterol and triglycerides and increases HDLcholesterol. 
Crestor zmanjšuje zvečano koncentracijo holesterola LDL, skupnega holesterola in trigliceridov ter zvečuje vrednost holesterola HDL.
Cytochrome P450 enzymes: Results from in vitro and in vivo studies show that rosuvastatin is neither an inhibitor nor an inducer of cytochrome P450 isoenzymes. 
Encimi citokroma P450: V raziskavah in vitro in in vivo so ugotovili, da rosuvastatin ni niti zaviralec niti induktor izoencimov citokroma P450.
Crestor is contraindicated in pregnancy and lactation. 
Uporaba Crestorja med nosečnostjo in dojenjem je kontraindicirana.
The choice of start dose in the individual patient should take into account aspects of efficacy and safety, as detailed in the SPC. 
Pri izbiri začetnega odmerka pri posameznem bolniku je treba upoštevati vidike učinkovitosti in varnosti, kakor je opisano v Povzetku glavnih značilnosti zdravila.
CYP2C9 was the principal isoenzyme involved, with 2C19, 3A4 and 2D6 involved to a lesser extent. 
Glavni izoencim, ki sodeluje, je CYP2C9, drugi, manj pomembni, pa so 2C19, 3A4 in
There are no data to support a steeper dose relationship for adverse reactions (myopathy, hepatotoxicity) for rosuvastatin, compared with other statins. 
V primerjavi z drugimi statini ni podatkov, ki bi podpirali močnejšo povezavo neželenih reakcij (miopatija, hepatotoksičnost) z odmerkom rosuvastatina.
4.4 Special warnings and special precautions for use 
4.4 Posebna opozorila in previdnostni ukrepi Vpliv na ledvice
From pooled phase III data, Crestor has been shown to be effective at treating the majority of patients with type IIa and IIb hypercholesterolaemia (mean baseline LDL-C about 4.8 mmol/l) to recognised European Atherosclerosis Society (EAS; 1998) guideline targets; about 80% of patients treated with 10 mg reached the EAS targets for LDL-C levels (<3 mmol/l). 
Atherosclerosis Society (EAS; 1998) učinkovito pri večini bolnikov s hiperholesterolemijo tipa IIa in IIb (srednja izhodiščna vrednost holesterola LDL približno 4,8 mmol/l); okoli 80 % bolnikov, ki so jemali po 10 mg zdravila, je po EAS doseglo ciljno vrednost za holesterol LDL (< 3 mmol/l).
Steady-state plasma concentrations of rosuvastatin in subjects undergoing haemodialysis were approximately 50% greater compared to healthy volunteers. 
Koncentracija rosuvastatina v stanju dinamičnega ravnovesja je bila pri ljudeh na hemodializi približno za 50 % večja kot pri zdravih prostovoljcih.